Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00935792
First received: July 6, 2009
Last updated: January 6, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2015
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)